Genedrive PLC (GB:GDR)
LSE:GDR
Want to see GB:GDR full AI Analyst Report?
Top Page
Genedrive
(LSE:GDR)
Select Model
Select Model
Rating:47Neutral
Price Target:
0.94 p
▲(6.36% Upside)
Action:ReiteratedDate:01/22/26
The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and a shrinking equity base despite minimal debt. Technicals are moderately supportive with price above key moving averages and positive MACD, but elevated RSI signals near-term overheating risk. Valuation remains challenging due to negative earnings (negative P/E).
Positive Factors
Recurring consumables revenue
Genedrive’s business model includes recurring revenue from single-use test cartridges tied to deployed instruments. Durable consumables sales create predictable revenue per installed device, supporting unit economics and revenue visibility as installations scale over months.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow indicate the business is not self-funding and remains dependent on external capital. Continued cash burn over several quarters risks dilution or funding gaps that could constrain commercial expansion or R&D investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue
Genedrive’s business model includes recurring revenue from single-use test cartridges tied to deployed instruments. Durable consumables sales create predictable revenue per installed device, supporting unit economics and revenue visibility as installations scale over months.
Read all positive factors
Genedrive (GDR) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£15.25M
Dividend YieldN/A
Average Volume (3M)49.58M
Price to Earnings (P/E)―
Beta (1Y)-0.99
Revenue Growth65.60%
EPS Growth74.84%
CountryUK
Employees43
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,605,568,200
10 Day Avg. Volume14,118,826
30 Day Avg. Volume49,583,488
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.48
Price to Sales (P/S)10.31
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genedrive Business Overview & Revenue Model
Company Description
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented...
How the Company Makes Money
Genedrive makes money primarily through (1) sales of its Genedrive diagnostic instruments (capital equipment placed with laboratories, hospitals, or clinics) and (2) recurring revenue from consumables—single-use/disposable test cartridges or assay...
Genedrive Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.07M | 764.00K | 501.00K | 55.00K | 49.00K | 687.00K |
| Gross Profit | 898.00K | 764.00K | 254.00K | -199.00K | -3.82M | -3.82M |
| EBITDA | -5.58M | -5.36M | -7.49M | -5.70M | -5.37M | -1.37M |
| Net Income | -5.34M | -5.23M | -7.08M | -5.15M | -4.67M | -691.00K |
Balance Sheet | ||||||
| Total Assets | 1.75M | 2.81M | 6.80M | 4.51M | 6.62M | 4.88M |
| Cash, Cash Equivalents and Short-Term Investments | 387.00K | 1.18M | 5.19M | 2.60M | 4.59M | 2.57M |
| Total Debt | 500.00K | 0.00 | 19.00K | 241.00K | 16.00K | 119.00K |
| Total Liabilities | 2.17M | 1.38M | 1.44M | 2.47M | 1.01M | 1.28M |
| Stockholders Equity | -415.00K | 1.44M | 5.36M | 2.04M | 5.61M | 3.59M |
Cash Flow | ||||||
| Free Cash Flow | -3.90M | -5.12M | -3.80M | -3.83M | -4.67M | -5.29M |
| Operating Cash Flow | -3.89M | -5.10M | -3.77M | -3.78M | -4.61M | -5.18M |
| Investing Cash Flow | -10.00K | -23.00K | 1.00K | -37.00K | 45.00K | 33.00K |
| Financing Cash Flow | 2.19M | 1.12M | 6.36M | 1.82M | 6.58M | -456.00K |
Genedrive Technical Analysis
Negative
0.88
Price Trends
1.03
Negative
0.99
Negative
0.89
Positive
Market Momentum
-0.02
Positive
42.94
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GDR, the sentiment is Negative. The current price of 0.88 is below the 20-day moving average (MA) of 0.98, below the 50-day MA of 1.03, and below the 200-day MA of 0.89, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.94 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GDR.
Genedrive Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £114.30M | 166.23 | 3.01% | ― | 2.73% | -65.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £21.34M | -2.69 | -58.27% | ― | 40.37% | -13.70% | |
49 Neutral | £1.15B | -2.82 | -29.43% | ― | 22.22% | 7.19% | |
47 Neutral | £15.25M | -0.76 | -153.92% | ― | 65.60% | 74.84% | |
40 Underperform | £21.59M | -6.19 | -213.66% | ― | 13.42% | 65.63% | |
39 Underperform | £7.87M | ― | 425.97% | ― | ― | ― |
* Healthcare Sector Average
GB:GDR
Genedrive
0.95
-0.53
-35.90%
GB:EKF
EKF Diagnostics Holdings
25.80
5.00
24.04%
GB:RENX
Renalytix
1.80
-6.20
-77.50%
GB:ABDX
Abingdon Health PLC
11.75
5.65
92.62%
GB:APTA
Aptamer Group Plc
0.60
0.23
62.16%
GB:ONT
Oxford Nanopore Technologies PLC
112.80
-13.40
-10.62%
Genedrive Corporate Events
Business Operations and StrategyProduct-Related Announcements
Genedrive Test Adopted as Routine Neonatal Service at Sussex NHS Trust
Positive
May 5, 2026
Genedrive plc said University Hospitals Sussex NHS Foundation Trust has moved its Genedrive MT-RNR1 ID kit for preventing antibiotic-induced hearing loss in neonatal intensive care units to a Business as Usual clinical service from 1 May 2026. The...
Business Operations and StrategyProduct-Related Announcements
Genedrive Positioned for NHS Tender as Rapid MT-RNR1 Test Expands Across UK NICUs
Positive
Apr 21, 2026
Genedrive, a Manchester-headquartered pharmacogenetic testing specialist focused on rapid point-of-care diagnostics for acute settings, already supplies two NICE-recommended genetic tests in NHS clinical use, targeting stroke treatment optimisatio...
Business Operations and Strategy
Genedrive Enhances Investor Hub to Deepen Shareholder Engagement
Positive
Apr 20, 2026
Genedrive plc has upgraded its interactive investor hub, aiming to make it a centralised platform for shareholder communication as the company advances its commercial and clinical activities in pharmacogenetic testing. The hub allows investors to ...
Business Operations and StrategyProduct-Related Announcements
Genedrive Secures Charity-Backed Rollout of Stroke Test at Bristol’s Southmead Hospital
Positive
Apr 16, 2026
Genedrive plc’s CYP2C19 ID Kit is set to be implemented at North Bristol NHS Trust’s Southmead Hospital Hyperacute and Acute Stroke Units, backed by £80,000 in funding from the Medlock Charitable Trust, whose chair David Medlock i...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Genedrive bolsters finances as NHS and global pilots drive uptake of rapid genetic tests
Positive
Mar 30, 2026
Genedrive reported interim results to 31 December 2025, highlighting increased revenue but a stable operating loss as it invests in commercial expansion for its CYP2C19 and MT-RNR1 pharmacogenetic tests in the UK and abroad. The company has secure...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Genedrive shareholders back fundraising as company expands pharmacogenetic footprint
Positive
Mar 9, 2026
Genedrive plc, a Manchester‑based pharmacogenetic testing specialist, develops and commercialises rapid, low‑cost point‑of‑care genetic tests that enable clinicians to tailor drug choice and dosage, with a focus on emergenc...
Business Operations and StrategyPrivate Placements and Financing
Genedrive Raises £5.26 Million to Bolster Point-of-Care Pharmacogenetics Push
Positive
Mar 9, 2026
Genedrive plc, a UK-listed point-of-care pharmacogenetic testing specialist, focuses on rapid, low-cost genetic diagnostics that enable clinicians to tailor drug choice and dosage, with particular emphasis on emergency healthcare settings. The com...
Delistings and Listing ChangesPrivate Placements and FinancingShareholder Meetings
Genedrive completes £500,000 placing as part of wider AIM fundraising
Positive
Feb 13, 2026
Genedrive has completed a placing of 50,000,000 new shares at 1.0 pence each, raising gross proceeds of £500,000 as part of a wider fundraising package that also includes a proposed £3.5 million direct subscription and an open offer of u...
Business Operations and StrategyPrivate Placements and Financing
Genedrive launches £5.5m fundraise to drive pharmacogenetic growth
Negative
Feb 13, 2026
Genedrive plc plans to raise up to £5.5 million through a combination of a direct subscription, a conditional placing and an open offer to existing shareholders, all priced at 1.0 pence per new share, a 7.4% discount to the latest closing pri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.